Therapeutic Purpose of Felodip

Felodip is a medication belonging to the class of calcium channel blockers, specifically the dihydropyridine derivative group. It is primarily utilized in cardiovascular medicine to manage conditions related to elevated blood pressure and certain types of chest pain. By influencing the movement of calcium into the smooth muscle cells of the arterial walls, the medication helps to facilitate vascular relaxation.

Principal Applications

Hypertension

The primary use of Felodip is the treatment of essential hypertension (high blood pressure). It acts by reducing peripheral vascular resistance, which lowers the pressure against which the heart must pump. This effect helps maintain blood pressure within a target range, which is a key factor in long-term cardiovascular health management. It may be used as a standalone option or in combination with other types of antihypertensive agents.

Stable Angina Pectoris

Felodip is also indicated for the management of chronic stable angina pectoris. In this context, the medication works by improving the balance between myocardial oxygen supply and demand. By dilating the coronary arteries and reducing the workload on the heart, it helps to prevent or reduce the frequency of angina attacks—the chest discomfort that occurs when the heart muscle does not receive enough oxygen-rich blood.

Mechanism of Action and Benefits

• Vascular Selectivity: Felodip is characterized by a high degree of selectivity for the smooth muscles of the blood vessels compared to the heart muscle itself. This allows for effective blood pressure reduction with minimal direct impact on cardiac contractility or conduction.
• Vasodilation: The medication promotes the widening of systemic arteries and arterioles. This relaxation results in decreased systemic vascular resistance, leading to a consistent antihypertensive effect.
• Improved Blood Flow: By reducing the resistance in the coronary arteries, the medication supports better oxygen delivery to the heart tissue, which is beneficial for individuals experiencing exercise-induced chest pain.
• Sustained Effect: Many formulations of this medication are designed to provide a steady release of the active ingredient, allowing for stable control of blood pressure levels throughout the day.

The official regulatory documents establish strict rules concerning who can and cannot use Фелодип (Felodipine). Use is generally restricted to adults being treated for arterial hypertension or chronic, stable angina pectoris.

Absolute Contraindications (Must Not Use)

Status/Condition	Regulatory Rule
Hypersensitivity	Prohibited
Pregnancy	Contraindicated
Acute Heart Conditions	Prohibited (e.g., unstable angina, acute MI, decompensated heart failure, cardiac outflow obstruction, cardiogenic shock)
Organ Dysfunction	Contraindicated in severe hepatic impairment

Use in the pediatric population (children) is not recommended because the drug's safety and efficacy have not been established. Similarly, the medicine is not recommended for women who are breastfeeding.

Special consideration is required for older adults and patients with mild to moderate hepatic impairment, who may require a lower initial starting dose. Caution is also advised when the drug is used by individuals with severe renal impairment or compromised ventricular function.

Interactions with other medicines and products

The official interaction profile for Felodipine is defined primarily by its clearance pathway, which is heavily dependent on the CYP3A4 enzyme system, as established in government regulatory documents. The interaction outcomes are classified into pharmacokinetic and pharmacodynamic effects.

Contraindicated and Exposure-Modifying Combinations

Substance Category	Outcome Description	Regulatory Status
Strong CYP3A4 Inducers	Cause a significant reduction in Felodipine plasma concentration and therapeutic effect.	Contraindicated
Strong CYP3A4 Inhibitors	Cause a significant increase in Felodipine plasma concentration (AUC/Cmax).	Requires official oversight

Co-administration with strong CYP3A4 inducers, specifically Rifampicin, Carbamazepine, Phenytoin, and the herbal product St. John’s Wort, is prohibited. Conversely, inhibitors such as azole antifungals (e.g., Itraconazole) and certain macrolide antibiotics (e.g., Erythromycin) elevate exposure.

Other Documented Interactions

Co-administration with other antihypertensive agents or alpha-blockers results in a pharmacodynamic additive effect, causing a reinforced reduction in systemic blood pressure. Ingestion of Grapefruit Juice is restricted as it significantly increases Felodipine plasma levels. Furthermore, Felodipine co-administration causes a small increase in the plasma concentration of Digoxin. Interaction resulting in increased exposure may be more pronounced in patients with severe hepatic impairment.

Modulation of Vascular Calcium Channels

This domain involves the drug's action as a dihydropyridine calcium channel blocker which specifically targets the L-type voltage-gated calcium channels in arterial smooth muscle cells. The resulting mechanistic cascade blocks calcium ion influx, which inhibits smooth muscle cell contraction and mediates arteriolar smooth muscle relaxation.

---

Regulation of Peripheral Vascular Resistance

The core pathway effect stems from the selective relaxation of arteriolar smooth muscle. By decreasing the contractile tone of these resistance vessels, the drug engages mechanisms that mediate a reduction in systemic vascular resistance. This pathway adjustment modulates systemic vascular resistance, which mechanically decreases myocardial wall tension.

---

Selective Arterial Dilation

A key mechanistic distinction is the drug's preferential action on arterioles compared to veins and its minimal effect on cardiac conduction at therapeutic concentrations. This selectivity modulates vascular processes primarily driven by arterial vasoconstriction, resulting in adjustments to the vasomotor tone within the peripheral circulation.

The administration of Фелодип (Felodipine) follows the protocols for the prolonged-release oral tablet formulation. These instructions emphasize a fixed, once-daily procedural structure to ensure the correct extended release of the medication.

Official Administration Guidelines

Procedural Step	Administration Protocol
Route & Frequency	Administered orally once daily.
Timing & Meals	Take in the morning. Should be taken without food or with a light meal that is not high in fat or carbohydrates.
Preparation	The prolonged-release tablet must be swallowed whole with water. Do not divide, crush, or chew the tablet.

Dosing and Special Conditions

• Adult Dosing: The typical initial adult dose is 5 mg once daily. The maintenance dose is usually 5–10 mg once daily, and the dose should be adjusted based on individual response. Doses higher than 20 mg are generally not recommended.
• Elderly and Hepatic Impairment: Treatment should generally be initiated with the lowest available dose (e.g., 2.5 mg once daily) in elderly patients or those with impaired liver function, as they may have elevated plasma concentrations.
• Missed Dose: If a dose is missed, skip the missed dose and take the next dose at the regularly scheduled time the following day. A double dose must not be taken to compensate for the missed one.
• Special Caution: Avoid consuming grapefruit or grapefruit juice, as this can increase the plasma concentrations of the drug and may increase the risk of adverse effects.

Research Evidence / Overview of Studies for Фелодип (Felodipine)

This overview describes the types of scientific research conducted on Felodipine, focusing on the available evidence regarding its use in approved conditions and what remains to be fully understood, without providing clinical advice or making claims about personal outcomes.

---

Evidence for Use in Arterial Hypertension (High Blood Pressure)

Research exploring the use of Felodipine in managing Arterial Hypertension includes a large number of Randomized Controlled Trials (RCTs). These studies, often comparing the drug against an inactive substance or other established treatments, were used in research exploring how blood pressure measurements change over defined time intervals. Many studies focused on adults with high blood pressure.

The main outcomes researchers monitored were the Systolic and Diastolic Blood Pressure readings. Studies reported patterns where participants' blood pressure measurements were observed to change during the trial period. The evidence contributes to understanding how the modified-release formulation was studied to provide consistent delivery.

Evidence for Use in Chronic Stable Angina Pectoris

Felodipine was evaluated in studies for patients with Chronic Stable Angina Pectoris, a condition involving periods of heightened symptoms, typically brought on by physical activity. The key functional outcome studied was Exercise Tolerance Time—researchers monitored how long patients could perform standardized exercise. Other study outcomes examined included patient-reported outcomes describing perceived discomfort and the measured frequency of angina episodes. Studies report how symptoms evolved in the observed populations, and findings describe patterns in which measurements of functional capacity evolved.

---

Long-Term Studies and Follow-Up Data

Longer research periods are particularly relevant for a condition like high blood pressure. Trials like the Felodipine Event Reduction (FEVER) Study research examined large populations of hypertensive patients over multiple years, tracking measurements related to the incidence of cardiovascular events and all-cause mortality. The evidence from these extended studies helps provide context on the durability of the observed responses to treatment. For the angina indication, long-term studies are more limited, meaning that long-term outcomes for this specific condition are not fully established.

---

What Research Gaps and Uncertainties Remain

Research related to blood pressure management has a long history, but some areas remain where research is ongoing or still emerging. Long-term comparative evidence is sometimes lacking, meaning there are limited head-to-head outcome studies comparing Felodipine against all of the newest antihypertensive agents on the market. Data for certain groups remain insufficient, particularly for patients with very advanced or complicated concurrent cardiovascular or renal diseases. Results apply only to the populations studied and do not offer personal predictions for these severe cases.

Key Studies & References

1. Felodipine - StatPearls (Source used for general clinical context and population data)

Common questions about Фелодип (FAQ)

Q: What is the main condition or disease Felodipine is used to treat?

According to official product information, Felodipine is primarily indicated for the treatment of hypertension, or high blood pressure. It is also approved for the management of chronic stable angina pectoris. These conditions are listed on the official product label as the indications for use.

---

Q: Can I drink alcohol while I'm on this treatment?

Official safety information indicates that alcohol consumption can cause an additive effect, potentially increasing the blood pressure-lowering action of the medication. This reinforced effect may lead to feeling unusually dizzy or light-headed. Consultation with a healthcare provider is recommended for personalized advice on alcohol use.

---

Q: How long does it typically take for Felodipine to start lowering my blood pressure after I start treatment?

Regulatory documents state that a reduction in blood pressure typically begins to occur within two to five hours after taking the tablet. The extended-release design aims to provide sustained blood pressure effect over a 24-hour period with consistent, once-daily use.

---

Q: Is there a specific time of day I should take my morning dose?

The official administration guidelines advise that the tablet should be taken once a day in the morning. Taking the dose around the same time each day may help maintain a consistent routine and steady levels of the medication.

---

Q: What should I do if my tablet is accidentally split or broken before I take it?

The prolonged-release tablet is strictly designed to be swallowed whole and must not be divided, crushed, or chewed. Breaking the tablet will interfere with the way the medicine is slowly released over the day. The official product information does not provide specific instructions for how to handle an accidentally broken tablet.

---

Q: What are the signs of an allergic reaction to Felodipine?

Though rare, the official safety data includes the potential for severe hypersensitivity reactions. Signs of a serious allergic reaction may include hives, swelling of the face, lips, tongue, or throat (angioedema), and difficulty breathing or swallowing. If any of these signs are observed, immediate medical attention is necessary.

How to Store and Dispose of Felodipine

Official regulatory guidelines mandate specific storage and disposal procedures for Felodipine extended-release tablets to maintain product stability and safety.

Storage Requirements

Felodipine must be stored at controlled room temperature, generally between 20 C and 25 C (68 F and 77 F). The medication must be kept in its original container, tightly closed, and protected from environmental factors. Regulatory sources strictly require storage away from excess heat, moisture, and freezing temperatures. The container must be kept out of the reach and sight of children in a safe, secure location.

Handling and Disposal

To preserve the extended-release formulation, the tablets must be swallowed whole and should not be split, chewed, or crushed. Do not keep medicine that is outdated or expired. Disposal must be done safely by following instructions from a healthcare professional or utilizing an official drug take-back program.